Human Biome Institute

Human Biome (HBI) is a third-generation microbiome company developing the world’s first biosynthetic, donor-independent, bio-mimetic microbiome biotherapeutics—internally referred to as New-Generation Biotherapeutics (NGBs). These autonomous products are designed to restore full microbiota ecosystem functionality while delivering indication-specific biological effects, guided by AI-based predictions.

Built on more than a decade of expertise in microbiota transplantation, antibiotic resistance, immunology, oncology, and transplantation medicine, HBI takes a deep-tech approach that goes beyond current microbiome drug standards. Its proprietary platform integrates four core modules—proof-of-concept, biobanking, computational modeling, and genomic-culturomics—and follows a strict strain-dependence principle. All NGB components are validated through in-house, high-viability donor-derived microbiota products (Mbiotix) in proof-of-concept clinical studies.

By combining AI, synthetic biology, and high-throughput automation, HBI sets a new benchmark in microbiome drug discovery. The company positions itself as a technology-platform leader, with priority focus areas including infection prevention and antimicrobial resistance, immuno-oncology, healthy ageing and longevity, and autoimmune diseases.